NEW SYNTHESIS OF FUCOSE
    32.
    发明申请
    NEW SYNTHESIS OF FUCOSE 审中-公开
    FUCOSE的新合成

    公开(公告)号:WO2013046181A1

    公开(公告)日:2013-04-04

    申请号:PCT/IB2012/055211

    申请日:2012-09-28

    Abstract: The present invention provides a process for converting D-glucose into L-fucose, where a first aspect of the invention relates to a method of making a compound of formula (1) wherein R is independently H,alkyl or phenyl or, preferably, wherein the two germinal R groups together with the carbon atom to which they are attached form a C3-s cycloalkylidene group, comprising the step of treating a compound of formula (2) wherein R is defined above and R 1 is a sulphonate leaving group, with a reducing complex metal hydride and, preferably, a base to form the compound of formula (1); a compound of formula (13).

    Abstract translation: 本发明提供了将D-葡萄糖转化为L-岩藻糖的方法,其中本发明的第一方面涉及制备式(1)化合物的方法,其中R独立地为H,烷基或苯基,或优选地,其中 两个生发R基团与它们所连接的碳原子一起形成一个C3-亚环烷基,其包括处理式(2)化合物的步骤,其中R定义如上,R1是磺酸根离去基团, 还原复合金属氢化物,优选碱形成式(1)化合物; 式(13)的化合物。

    HMO PRODUCTION
    38.
    发明申请
    HMO PRODUCTION 审中-公开

    公开(公告)号:WO2021148611A1

    公开(公告)日:2021-07-29

    申请号:PCT/EP2021/051468

    申请日:2021-01-22

    Applicant: GLYCOM A/S

    Abstract: The present inventive concept relates to a genetically modified cell enabled for the production of an oligosaccharide, preferably, an HMO, comprising a recombinant nucleic acid encoding a protein of the MFS superfamily; and methods using said cell for the production the oligosaccharide, preferably an HMO.

    MIXTURE OF HMOS FOR TREATING AUTOIMMUNE DISEASES

    公开(公告)号:WO2019229711A1

    公开(公告)日:2019-12-05

    申请号:PCT/IB2019/054522

    申请日:2019-05-31

    Applicant: GLYCOM A/S

    Abstract: The invention relates to a method, compounds and compositions for the secondary prevention, treatment or dietary management of symptomatic and asymptomatic non -intestinal autoimmune diseases in a non-infant human including Sjogren's syndrome and type 1 diabetes. Said method, compounds and compositions for the secondary prevention, treatment or dietary management include human milk oligosaccharide (HMO), preferably mixtures of human milk oligosaccharides selected from the group of 2'-FL, LNnT, LNT, DFL, and 6'-SL.

    NUCLEIC ACID CONSTRUCT FOR IN VITRO AND IN VIVO GENE EXPRESSION

    公开(公告)号:WO2019123324A1

    公开(公告)日:2019-06-27

    申请号:PCT/IB2018/060355

    申请日:2018-12-19

    Applicant: GLYCOM A/S

    Abstract: The present invention relates to the field of recombinant production of biological molecules in host cells. The invention provides nucleic acid constructs that allow to modify expression of a desired gene using both in vitro and in vivo gene expression systems. The constructs can advantageously be used to produce a variety of biological molecules recombinantly in industrial scales, e.g. human milk oligosaccharides (HMO).

Patent Agency Ranking